{
    "2018-04-15": [
        [
            {
                "time": "",
                "original_text": "[买入评级]贝达药业(300558)：临床推进顺利 股权激励释放新动力",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "临床推进",
                        "股权激励",
                        "新动力"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[买入评级]贝达药业(300558)年报点评：2017年收入符合预期 期待新药上市",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "年报",
                        "2017年收入",
                        "新药上市"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}